T he clinical manifestations, underlying pathology and aetiology of human diabetic neuropathy are varied and complex. Much data has been generated from preclinical models to provide a conceptual framework for the cause and treatment of human diabetic neuropathy. Despite this there remains much debate and controversy on the pathophysiology of the condition. Furthermore, many of the interventions reaching phase III clinical trials have failed to prove effective. To date we have no evidence-based and effective treatment(s) for human diabetic neuropathy. Br J Diabetes Vasc Dis 2003;3:107-11 
Introduction
Much data has been generated from animal models and cell culture, to provide a conceptual framework for the cause and treatment of diabetic neuropathy. 1 However, limited translational work in diabetic patients continues to generate debate and controversy over the cause(s) of human diabetic neuropathy. Changes in metabolic pathways so often demonstrated in animal models have only partially been verified in man. Clinical trials of therapeutic agents designed to reverse these abnormalities have been undertaken prematurely.
Metabolic Hyperglycaemia
Epidemiological data lend support to the contention that the duration and severity of exposure to hyperglycaemia is related to the severity of neuropathy in man. 2 In a study of patients with newly diagnosed type 2 diabetes who were assessed at baseline, five and 10 years, the development of neuropathy was related to hypoinsulinaemia although the overall severity of neuropathy was related to poorer glycaemic control. 3 This suggests that hyperglycaemia may not necessarily be fundamental to the development of human diabetic neuropathy but may play a major role in determining progression and hence severity of nerve damage. In a recent study of subjects with and without impaired glucose tolerance (IGT), sural nerve amplitude, and myelinated fibre density did not differ, suggesting a glycaemic threshold for the development of neuropathy. 4 In contrast, of 121 patients with a small fibre painful neuropathy and electrodiagnostic evidence of axonal injury who had normal fasting glucose and HbA 1C , 25% had IGT. 5 Furthermore, a subgroup of the patients with IGT had epidermal nerve fibre abnormalities. 6 Improving glycaemic control improved clinical and neurophysiological measures of neuropathy in patients with type 1 diabetes in the DCCT, 7 and after pancreatic transplantation. 8 There are limited interventional data in type 2 diabetes, but in VA CSDM 153 patients were randomised to intensive versus conventional therapy and achieved a 2.07% difference in HbA 1C over two years, but failed to demonstrate a significant difference in the progression of either somatic or autonomic neuropathy. 9 The UKPDS represents the largest interventional study in type 2 diabetes, to assess the effects of improved glycaemic control, but the neuropathy data await analysis.
ing to accumulation of sorbitol and fructose respectively. This is associated with a reduction in nerve conduction velocity (NCV).
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Blockade of this pathway with aldose reductase inhibitors (ARI's) ameliorates the NCV deficit. 12 A recent study has demonstrated enhanced aldose reductase but minimal sorbitol dehydrogenase expression in the peripheral nerves of diabetic patients. 13 In one of the earliest clinical studies, sorbitol and fructose levels were increased in only 1/3 of the sural nerves from 20 patients with predominantly type 2 diabetes and could not be related to clinical, neurophysiological, or pathological severity of neuropathy.
14 However, at post-mortem sciatic nerves from diabetic patients showed increased glucose, fructose and sorbitol content compared to normal subjects. 15 In biopsies of peripheral nerve obtained at amputation, glucose fructose and sorbitol were significantly higher in diabetic than non-diabetic patients, 16 but concentrations differed markedly from previously reported values in human nerve obtained at post-mortem. 15 In a recent study of patients with normal glucose tolerance, IGT and type 2 diabetes only the diabetic patients demonstrated an elevation in nerve sorbitol, suggestive of a glycaemic threshold for activation of this pathway. 4 In an interventional study with the ARI sorbinil, at baseline, sural nerve biopsies from diabetic patients with neuropathy demonstrated significantly higher endoneurial sorbitol and fructose levels, and linear regression analysis demonstrated a significant inverse correlation between nerve sorbitol and the number of myelinated fibres. 17 Despite these inconsistent findings in diabetic patients, over the last 20 years pharmaceutical companies have actively pursued clinical trial programmes with ARIs. 11 A recent meta-analysis of all randomised controlled trials of ARI versus placebo, no treatment or other treatment in diabetic patients with or without clinical neuropathy identified 19 trials, testing four different ARI's for between four to 208 weeks duration (median 24 weeks) and demonstrated a small but significant reduction in decline of median (0.66 m/s 95% CI 0.18-1.14 m/s) and peroneal (0.53 m/s 95% CI 0.02-1.04 m/s) motor nerve conduction velocity without benefit in either of the sensory nerves. 18 The clinical relevance of an effect on motor but not sensory nerve function is questionable, especially as the latter is primarily responsible for the most common manifestations of human diabetic neuropathy: severe pain and the insensate extremity which may lead to ulceration and eventual amputation. 19 By contrast, ARI's have been shown to benefit those with mild neuropathy, when there is significant aldose reductase inhibition and perhaps in those who are at greatest risk of developing the complications through a higher set-point for aldose reductase activity. 20 Thus, in a randomised, double-blind placebo controlled trial of sorbinil (an ARI), even a moderate decrease of 41.8 + 8.0% in nerve sorbitol content was associated with a 3.8-fold increase in the percentage of regenerating myelinated nerve fibres, along with a quantitative improvement in paranodal demyelination, segmental demyelination, and myelin wrinkling which was related to electrophysiological and clinical evidence of improved nerve function. 21 In a 52-week, randomised, placebo-controlled, double-blind, multiple-dose, clinical trial with the ARI, Zenarestat, dose-dependent increments in sural nerve sorbitol suppression were accompanied by significant improvement in NCV. 22 In a secondary analysis, Zenarestat doses producing > 80% sorbitol suppression were associated with an increase in the density of small-diameter myelinated fibres in the sural nerve. 22 Similarly in 279 diabetic patients with neuropathy, over 52 weeks, the ARI Fidarestat produced a significant improvement in median nerve F-wave conduction velocity (FCV) and minimal latency as well as symptoms (numbness, spontaneous pain, sensation of rigidity, paraesthesiae in the sole on walking, and hyperaesthesia). 
Myoinositol
Myoinositol deficiency has been proposed to play a role in the pathogenesis of diabetic neuropathy. Although an early nerve biopsy study reported normal myoinositol levels in diabetic 14 a post-mortem study showed that concentrations of free and lipid inositol were lower in nerves of diabetic patients. 15 In biopsies taken at amputation no significant difference was found in myoinositol concentration. 16 In a nerve biopsy study of diabetic patients with and without neuropathy, myoinositol levels were not decreased and were not associated with the severity of neuropathology. 17 In the same issue of the journal proponents of the myoinositol theory failed to publish their results in sural nerve biopsies. 21 Furthermore, in a recent sural nerve biopsy study myoinositol levels did not differ between normal, IGT and type 2 diabetic subjects. 4 
Glycation
Hyperglycaemia results in the formation of advanced glycation end-products (AGE's), which in turn act on specific receptors (RAGE) to activate, monocytes and endothelial cells increasing the production of cytokines, adhesion molecules and tissue growth factor. 24 Glycation has also recently been shown to have an effect on matrix metalloproteinases (MMPs), in particular MMP-2 which degrades type IV collagen but also membrane type 1 MMP, tissue inhibitors of MMPs (TIMP)-1 and -2, and transforming growth factor-beta (TGF-β). 25 Other effects include prevention of epidermal growth factor induced autophosphorylation and activation of extracellular signal-regulated kinases. 26 In experimental diabetes these changes can be prevented by AGE inhibitors such as the nucleophilic compounds pyridoxamine, tenilsetam, 2,3-diaminophenazone, OPB-9195 or aminoguanidine. 25, 26 Alternatively the administration of recombinant RAGE hinders the AGE-RAGE interaction. 25, 26 Human sural nerves obtained from diabetic and non-diabetic amputation specimens contained normal furosine; (an early reversible glycation product) and elevated pentosidine levels in both cytoskeletal and myelin protein. 27 Enhanced staining for carboxymethyllysine in the perineurium, endothelial cells and pericytes of endoneurial microvessels as well as myelinated and unmyelinated fibres has been shown to correlate with a reduction in myelinated fibre density in peripheral nerves from type 2 diabetic (n=5) compared with non-diabetic control (n=5) subjects. 28 Pyrraline, an AGE, was also increased in post-mortem samples of optic nerve from diabetic patients. 29 ACTION II, which ended in March 1998, compared two dose levels of aminoguanidine with placebo on the progression of nephropathy in 599 type 2 diabetic patients with established renal disease, 30 but data have yet to be published. 31 Pyridoxamine dihydrochloride (HCl), a new anti-glycation agent, has been given fast-track status by the FDA for phase II clinical trials in diabetic nephropathy. No trial data are currently available for human diabetic neuropathy.
Oxidative stress
An increasing body of data supports the role of oxidative stress in the pathogenesis of diabetic neuropathy in pre-clinical models, 1 but clinical evidence is less compelling. However, benefits have been observed with alpha-lipoic acid, a powerful antioxidant that scavenges hydroxyl radicals, superoxide and peroxyl radicals and regenerates glutathione. 32 A number of randomised, double-blind placebo-controlled trials have been conducted with alpha-lipoic acid in diabetic neuropathy. The ALADIN study assessed the effects of intravenous (i.v.) alpha-lipoic acid over three weeks and demonstrated an improvement in neuropathic symptoms. 33 In the ORPIL study, oral alpha-lipoic acid was compared with placebo for three weeks and improvements in total symptom and neuropathy disability scores (NDS) were noted. 34 In ALADIN-II, diabetic patients with symptomatic polyneuropathy were randomly assigned to five days of i.v. alpha-lipoic acid followed by oral treatment for two years and demonstrated a significant improvement in sural NCV, sensory nerve action potential (SNAP) and tibial motor nerve conduction velocity (MNCV) but not NDS. 35 ALADIN-III randomised 509 diabetic patients to i.v. alpha-lipoic acid for three weeks, followed by oral treatment three times daily for six months. There was no change in the total symptom score, but i.v. therapy improved the neuropathy impairment score, and improvement was maintained until the end of the study.
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Vascular factors
There is a large body of data implicating vascular disease in the pathogenesis of diabetic neuropathy. 37 The most direct evidence that improving tissue blood flow may improve diabetic neuropathy is derived from large vessel revascularisation studies which have shown improved NCV in some 38 but not all studies. 39 A longer-term follow-up of the latter study showed prevention of worsening of peroneal NCV.
40
ACE inhibitors
Angiotensin-converting enzyme (ACE) inhibitors mediate increased flow-dependent release of endothelium-derived relaxing factor (EDRF) and endothelium dependent vessel relaxation. 41 In an open-label, dose escalation study with lisinopril, after 12 weeks there was a significant improvement in median motor and sensory, peroneal motor and sural sensory NCVs as well as warm thermal discrimination threshold (TDT) and vibration perception threshold (VPT) after 12 weeks. 42 Another open-label study showed that lisinopril improved thermal and pain thresholds. 43 In a 12-month, double-blind, placebo-controlled, clinical trial of trandalopril, peroneal motor NCV, M-wave amplitude F-wave latency and sural nerve amplitude improved significantly. 44 More recently, the ABCD trial assessed the effects of intensive versus moderate blood pressure control with either nisoldipine or enalapril and surprisingly showed no difference with regard to the progression of diabetic nephropathy, retinopathy or neuropathy. 45 
PKC beta inhibitors
1, 2-diacylglycerol (DAG) induced activation of protein kinase C (PKC); in particular PKCβ, has been proposed as having a major role in diabetic neuropathy. 1 However, even in nerves from diabetic animals a fall in DAG levels and a consistent pattern of change in PKC activity has not been observed. 46 Despite this, inhibition of PKCβ in diabetic rats appears to correct reduced nerve blood flow and NCV. 12 Data from Phase II clinical trials demonstrate some benefit in diabetic patients with neuropathy. 47 Based 
Hydroxymethylglutaryl CoA reductase inhibitor
An increasing body of evidence suggests that conventional risk factors for macrovascular disease such as deranged lipids are also important in the pathogenesis and progression of human diabetic neuropathy. 48 Conventional wisdom suggests that hydroxymethylglutaryl CoA reductase inhibitors benefit patients principally by reducing low density lipoprotein (LDL) levels. However, recent studies show that this class of compounds can completely prevent AGE-induced nuclear factor kappa B (NFκB) induced protein-1 activation and up-regulation of vascular endothelial growth factor (VEGF) mRNA, in microvascular endothelial cells. 49 Over two years simvastatin therapy has shown a trend towards slower progression of neuropathy, measured by vibration perception threshold, but no change in the status of clinical neuropathy.
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Neurotrophins
Neurotrophins promote the survival of specific neuronal populations by inducing morphological differentiation, enhancing nerve regeneration, stimulating neurotransmitter expression, and altering the physiological characteristics of neurones. 51 In an initial study the skin of diabetic patients with sensory fibre dysfunction demonstrated a depletion of nerve growth factor (NGF). 52 However, subsequently other studies in diabetic patients have shown a significant increase in skin NGF mRNA, 53 neurotrophin-3 (NT-3), 54 and normal sciatic nerve ciliary neurotrophic factor levels. 55 In situ hybridisation studies have also demonstrated an increased expression of both trkA, the high-affinity receptor for NGF, and trkC, the receptor for NT-3, in the skin of diabetic patients. 56 Despite these apparently contradictory findings, a phase II trial of recombinant human nerve growth factor in 250 diabetic patients with symptomatic diabetic polyneuropathy, demonstrated an improvement in the sensory component of the neurological examination, (two quantitative sensory tests), and in a rather vague end point 'the clinical impression of most subjects that their neuropathy had improved'. 57 Subsequently, a phase III trial in 1,019 diabetic patients with sensory polyneuropathy failed to demonstrate a significant benefit. 58 More recently a randomised, double-blind, placebo-controlled study of brain-derived neurotrophic factor in 30 diabetic patients demonstrated no improvement in nerve conduction, quantitative sensory and autonomic function tests including the cutaneous axon-reflex. 59 In conclusion, our failure to develop an effective treatment for human diabetic neuropathy is based on: G Ineffective translation of experimental studies to the diabetic patient. G Failure to take heed of the often-contradictory findings in the patient (lack of sorbitol accumulation in some human nerve biopsy studies -ARI's, no evidence of a deficit in neurotrophins or expression of their receptors -recombinant human nerve growth factor) before embarking on clinical intervention trials.
